Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Based on market data through Oct 27, 2026, StockInvest.us rates Ironwood Pharmaceuticals (IRWD) as a Sell Candidate with a technical score of -1.67 on its -10 to +10 scale. The rating is unchanged ...

Stay ahead of the weather in Ironwood with FOX Weather's local weather radar maps. Use our interactive Doppler radar for Ironwood, MI to get real-time updates on rain, snow, and clear skies in your ...

Gastrointestinal disease specialist Ironwood Pharma has agreed a $1 billion deal to buy VectivBio and its drug candidate for short bowel syndrome (SBS), betting on positive results in a phase 3 trial ...

Neala Broderick is a Brooklyn-based food writer exploring the stories behind what we eat and why. She began working in restaurants at 14 and has since covered food and restaurants for TastingTable, ...

Ironwood Pharma has issued an upbeat assessment of phase 3 trial data with apraglutide for short bowel syndrome (SBS), but missed secondary outcome measures led to a sharp decline in its share price.

Mature ironwoods around Tucson make the oldest saguaros look like mere youngsters by comparison. “Estimates show some (ironwood) trees to be 800 years old, and it is likely that they live even longer, ...